{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-000427","form_type":"8-K","ticker":"AXSM","cik":"0001579428","company_name":"Axsome Therapeutics, Inc.","filed_at":"2023-01-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.685859+00:00","generated_at":"2026-06-20T17:50:05.132274+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"debt","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Axsome increases Hercules loan to $350M, cuts rate, extends maturity to 2028/2029","bullets":["Total loan commitment raised to $350M from $300M; interest rate is greater of 9.95% or prime+2.20%.","Maturity extended to Jan 1, 2028 (or Jan 1, 2029 if revenue targets met); minimum cash covenant $30M.","Company believes current cash plus remaining committed capital sufficient to fund operations to cash flow positivity.","Amended tranche structure with $95M, $55M, $30M, $35M, $35M sub-tranches for Tranche 1."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-000427","json":"https://secwatch.observer/filing/0000950170-23-000427.json","markdown":"https://secwatch.observer/filing/0000950170-23-000427.md","text":"https://secwatch.observer/filing/0000950170-23-000427.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1579428/000095017023000427/0000950170-23-000427-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1579428/000095017023000427/axsm-20230109.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T17:50:05.132274+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"65b5ffbbf15512708e2e0ec669d02dc9f9094d8c","claim":"Axsome Therapeutics, Inc. amended Third Amendment with Hercules Capital, Inc. valued at $350,000,000 (effective 2023-01-09).","evidence_excerpt":"On January 9, 2023, Axsome Therapeutics Inc., a Delaware corporation (the “Company”), entered into a Third Amendment (the “Third Amendment”) to its Loan and Security Agreement (the “Loan Agreement”) with Hercules Capital, Inc.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1579428/000095017023000427/0000950170-23-000427-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"amendment"},{"label":"Agreement","value":"credit facility"},{"label":"Counterparty","value":"Hercules Capital, Inc."},{"label":"Value","value":"$350,000,000"},{"label":"Effective","value":"2023-01-09"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}